Tomer Kariv - 30 Jan 2023 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: ELOX on Nasdaq
Reported as of: 30 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jan 2023, 15:08:40 UTC
Prior SEC filing: 30 Nov 2022
Next SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Sumit Aggarwal, Attorney-in-Fact for Tomer Kariv

Key filing fact

Tomer Kariv filed Form 4 for Eloxx Pharmaceuticals, Inc. on 31 Jan 2023.

Key facts

This page summarizes Tomer Kariv's Form 4 filing for Eloxx Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Jan 2023, 15:08.

Change

Previous filing in this sequence was filed on 30 Nov 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELOX transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +2,859
Change %
Price: $0.000000
Shares after: 2,859
Date: 30 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,859
Exercise price: $4.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Footnote F2

The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.

SEC remarks

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.